Trial · NCT00004031

SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

NCT00004031, Phase 3, Completed, SWOG Cancer Research Network; results first posted 2021-02-02

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma. Trials, record NCT00004031. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00004031

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT number: NCT00004031
Status: Completed
Phases: Phase 3
Enrollment: 397 participants, actual
Lead sponsor: SWOG Cancer Research Network
Conditions: Lymphoma
Interventions: rituximab, CHOP regimen, carmustine, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
First posted: 2003-01-27
Last updated: 2021-02-02
Results first posted: 2021-02-02

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	2-year Overall Survival Rates	up to 2 years post registration	Percentage of participants surviving 2 years post registration
Primary	2 Year Progression-free Survival	From registration until death	Percentage of participants without disease progression up to 2 years post-registration.
Secondary	Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs	Duration of treatment and follow up until death or 3 years post registration	Adverse Events (AEs) are reported by CTCAE Version 2.0. Only adverse events that are possibly, probably or definitely related to study drug are reported. Higher grades indicate higher severity of adverse events.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	2-year Overall Survival Rates	up to 2 years post registration	Eligible participants that were randomized to study arms.	percentage of participants	NUMBER
PRIMARY	2 Year Progression-free Survival	From registration until death	Eligible participants that were randomized to study arms.	percentage of participants	NUMBER
SECONDARY	Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs	Duration of treatment and follow up until death or 3 years post registration	Patients who received at least one dose of protocol treatment.	Participants	NUMBER

Source ClinicalTrials.gov

Results by group388

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
2-year Overall Survival Rates	CHOP/CHOP-R x 3		71.1	95% Confidence Interval 63.2 to 78.9	percentage of participants
2-year Overall Survival Rates	CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant		73.7	95% Confidence Interval 66.0 to 81.4	percentage of participants
2 Year Progression-free Survival	CHOP/CHOP-R x 3		55.4	95% Confidence Interval 46.9 to 64.1	percentage of participants
2 Year Progression-free Survival	CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant		69.1	95% Confidence Interval 61.0 to 77.1	percentage of participants
Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs	CHOP/CHOP-R x 3	Abdominal pain/cramping	8		Participants
Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs	CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant	Abdominal pain/cramping	9		Participants
Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs	CHOP/CHOP-R x 3	Alkaline phosphatase increase	9		Participants
Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs	CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant	Alkaline phosphatase increase	15		Participants
Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs	CHOP/CHOP-R x 3	Allergic reaction	0		Participants
Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs	CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant	Allergic reaction	8		Participants

1 to 10 of 388Source ClinicalTrials.gov

See all 388 results by group

Participant flow8

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	CHOP/CHOP-R x 3	128
Overall Study	STARTED	CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant	125
Overall Study	Assessed for Adverse Events	CHOP/CHOP-R x 3	123
Overall Study	Assessed for Adverse Events	CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant	113
Overall Study	COMPLETED	CHOP/CHOP-R x 3	103
Overall Study	COMPLETED	CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant	104
Overall Study	NOT COMPLETED	CHOP/CHOP-R x 3	25
Overall Study	NOT COMPLETED	CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant	21

Source ClinicalTrials.gov

Adverse events160

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anemia	Blood and lymphatic system disorders	CHOP/CHOP-R x 3	57	123
other	Anemia	Blood and lymphatic system disorders	CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant	89	113
other	Febrile neutropenia	Blood and lymphatic system disorders	CHOP/CHOP-R x 3	10	123
other	Febrile neutropenia	Blood and lymphatic system disorders	CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant	44	113
other	PRBC transfusion	Blood and lymphatic system disorders	CHOP/CHOP-R x 3	3	123
other	PRBC transfusion	Blood and lymphatic system disorders	CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant	32	113
other	Platelet transfusion	Blood and lymphatic system disorders	CHOP/CHOP-R x 3	2	123
other	Platelet transfusion	Blood and lymphatic system disorders	CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant	37	113
other	Sinus tachycardia	Cardiac disorders	CHOP/CHOP-R x 3	2	123
other	Sinus tachycardia	Cardiac disorders	CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant	12	113

1 to 10 of 160Source ClinicalTrials.gov

See all 160 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	CHOP/CHOP-R x 3	51	128
Total, all-cause mortality	CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant	39	125
Total, other adverse events	CHOP/CHOP-R x 3	108	123
Total, other adverse events	CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant	106	113
Total, serious adverse events	CHOP/CHOP-R x 3	4	123
Total, serious adverse events	CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant	4	113

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
24171516	DERIVED	PubMed
24625415	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U10CA032102	Southwest Oncology Group Treatment Grant	BLANKE, CHARLES D.	OREGON HEALTH & SCIENCE UNIVERSITY	NATIONAL CANCER INSTITUTE	1985 to 2013

Source NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
CHOP/CHOP-R x 3 vs CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant: deaths from any cause	Trial comparisons
CHOP/CHOP-R x 3 vs CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00004031

GET https://conductscience.org/api/trials/v1/NCT00004031/results?page=2

API reference For AI assistants